Macular Degeneration or ARMD

Macular degeneration is the leading cause of vision loss in Americans age 65 and older. It is a degeneration of the macula, which is the part of the retina where the cones are concentrated. This is the part of the retina where images come into focus for sharp central vision. Normally ARMD causes a slow painless loss of central vision. Symptoms include fuzzy or distorted vision. Macular Degeneration is associated with aging and seems to have a family tendency. Some risk factors for it are heredity, smoking, hypertension, lighter eye color and obesity.

There are two forms of macular degeneration, a dry form and a wet form. Dry ARMD is a nonvascular form and is caused by thinning and/or deposits of pigment in the macula. It causes a gradual vision loss, but is not as severe as wet macular degeneration. Wet or neovascular macular degeneration is more advanced and more damaging. In this form new blood vessels grow under the macula, which leak blood and fluid.

While there are no cures for macular degeneration, there are new treatments available which can stop the progression. These include new medications as well as Photodynamic Therapy.  Research has shown that certain nutients- lutein, zinc, zeaxanthin and vitamins can lower the risk or slow the progression.

For more information see  http://www.macular.org/

Vision News

  • Alcon Launches AcrySof(R) IQ ReSTOR(R) Toric Intraocular Lens Outside The United States
  • Starting The School Year Right
  • Drug Discovery Tools To Fight Cancer, Blindness To Be Discussed At UB Symposium
  • 'Back-To-School' How To Prevent Sports Related Eye Injuries
  • Carl Zeiss Meditec Is Shaping The Future Of Ophthalmology: Creating What's To Come
  • OptiMedica's Laser Cataract Surgery System To Be Featured In Three Clinical Presentations At ESCRS 2010
  • Dr. Tom Tooma Purchases Interest In All 12 Southern California TLC Laser Eye Centers, Changing Name To NVISION Laser Eye Centers
  • Bausch + Lomb Releases Single-Use Vitreoretinal Asymmetric Peeling Forceps
  • New Data Will Help Predict Vision Loss In Glaucoma
  • Proprietary Zinc/Phytase Formulation Improved Botulinum Toxin A Results
  • ReVision's Fenretinide (RT-101) Reduced Incidence Of Choroidal Neovascularization By More Than 50 Percent In Patients With Geographic Atrophy
  • Microplasmin Meets Primary Endpoint In Second Phase III Trial In VMA, Confirms Positive Findings Of First Trial
  • pSivida Announces Iluvien(R) Receives FDA Priority Review For Treatment Of Diabetic Macular Edema
  • Allergan Receives FDA Approval For LUMIGAN(R) 0.01% As First-Line Therapy Indicated For The Reduction Of Elevated Intraocular Pressure In Glaucoma
  • Improving Ocular Disease Screening By LED Illumination Of The Eye
  • Eyegenix™ Artificial Cornea Achieves Major Advancement Towards Curing Corneal Blindness
  • Diabetic Macular Edema Drug Iluvien Gets FDA Priority Review
  • Optometrists Encourage Eye Test For Children, Ireland
  • 'Toolbox Of MiniPromoters' For Gene Research And Therapy Unvelied By UBC Researchers
  • Revolutionary Way To Treat Eye Cancer May Prevent Blindness
  • More...